SPONSOR

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Total Trials

Recruiting

Phases

Phase 3, Phase 1, Phase 2, Phase 1, Phase 2

Conditions studied: Rheumatoid Arthritis Mastalgia Breast Neoplasms Early-stage Breast Cancer HER2-positive Breast Cancer Adjuvant Treatment After Trastuzumab RCB Classification 1-2 Neratini Age-related Hearing Loss Hearing Loss, Sensorineural

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is a clinical research sponsor with 27 registered studies on ClinicalTrials.gov, of which 27 are actively recruiting participants. Research covers conditions including Rheumatoid Arthritis, Mastalgia, Breast Neoplasms, Early-stage Breast Cancer.

The trial portfolio spans Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

How many clinical trials has Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University sponsored?

ClinicalMetric currently tracks 27 clinical trials sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, of which 27 are actively recruiting participants. These trials cover conditions including Rheumatoid Arthritis, Mastalgia, Breast Neoplasms. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University research focus on?

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University clinical trials span Rheumatoid Arthritis, Mastalgia, Breast Neoplasms, Early-stage Breast Cancer, HER2-positive Breast Cancer, and additional conditions. The research pipeline includes Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University clinical trial?

To participate in a Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials with current recruitment status updated daily.

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Frequently Asked Questions — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Clinical Trials by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis

External Mastalgia-oil Versus Placebo in Premenopausal Women With Severe Mastalgia

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Comparing the Efficacy of Domestic Versus Imported Hearing Aids in ARHL

Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases

DCNN Developed for Detection and Assessing the Perfusion of PTG

Herombopag Treated T-DM1 Induced Platelet Reduction

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

RC48 in Combination With AK104 and Bevacizumab in OCCC

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Preoperative Detection of Muscle Invasion in Bladder Cancer with Contrast-enhanced Ultrasonography

Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma

Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation

Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer

De-Escalation Postoperative Radiotherapy for Oral Squamous Cell Carcinoma With pCR/MPR.

Single-Incision Gasless Endoscopic Total Thyroidectomy Via Subclavian Approach Versus Open Surgery for PTC

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Clinical Eficacy of Extracorporeal Shock Wave Therapy on Patellar Tendinitis

Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC

Treatment of Mandibular Bone Cyst by Navigation and Endoscopy